Cancer Research Investment in Canada - Highlights November 2023

Slide Note
Embed
Share

The Canadian Cancer Research Alliance (CCRA) is a collaboration of organizations funding cancer research in Canada to advance prevention, diagnosis, and treatment. Established in 2005, CCRA has grown to over 35 members and published strategic plans to enhance cancer research outcomes. The Alliance supports initiatives like the Canadian Strategy for Cancer Control to reduce cancer incidence and improve survivor quality of life.


Uploaded on Mar 26, 2024 | 0 Views


Cancer Research Investment in Canada - Highlights November 2023

PowerPoint presentation about 'Cancer Research Investment in Canada - Highlights November 2023'. This presentation describes the topic on The Canadian Cancer Research Alliance (CCRA) is a collaboration of organizations funding cancer research in Canada to advance prevention, diagnosis, and treatment. Established in 2005, CCRA has grown to over 35 members and published strategic plans to enhance cancer research outcomes. The Alliance supports initiatives like the Canadian Strategy for Cancer Control to reduce cancer incidence and improve survivor quality of life.. Download this presentation absolutely free.

Presentation Transcript


  1. 1 Highlights November 2023 CANCER RESEARCH INVESTMENT IN CANADA, 2021

  2. 2 SLIDE INDEX This slide deck is intended as a companion to the dashboards and other analytical tools. It presents different graphs and analyses to complement the other outputs. Topic Background Methodology Overall Investment Highlights Areas of Science/CSO Highlights Cancer Sites Highlights Funding Mechanisms Highlights Overall Operating Grants Trainee Awards Career Awards Equipment/infrastructure grants and Research Support Fund Further information Slides 3, 4, 5 6, 7, 8, 9, 10, 11 12, 13, 14, 15, 16, 17, 18 19, 20, 21 22, 23, 24 25, 26, 27 28, 29, 30 31, 32, 33 34, 35 36, 37, 38 39, 40 Canadian Cancer Research Alliance

  3. 3 INTRODUCTION The CCRA is an alliance of organizations that collectively fund most of the cancer research conducted in Canada research that will lead to better ways to prevent, diagnose, and treat cancer and improve survivor outcomes. Members include federal research funding programs/agencies, provincial research agencies, provincial cancer care agencies, cancer charities, and other voluntary associations. Member are motivated by the belief that, through effective collaboration, Canadian cancer research funding organizations can maximize their collective impact on cancer control and accelerate discovery for the ultimate benefit of Canadians affected by cancer. The Executive Office is supported by the Canadian Partnership Against Cancer, funded by Health Canada to work with Canada s cancer community to implement the Canadian Strategy for Cancer Control to reduce the incidence of cancer, lessen the likelihood of Canadians dying from cancer, and enhance the quality of life of those affected by cancer. The Partnership is committed to enhancing the cancer research environment in Canada through its support of the CCRA and CCRA s role in coordinating the cancer research funding system. As a member and funder of the CCRA, the Partnership collaborates with other member organizations to enable the strategy for cancer research in Canada. Canadian Cancer Research Alliance

  4. 4 SINCE 2005 The Alliance has grown from 23 members to over 35 members since its inception. The investment survey, the first joint activity of CCRA members, was first published in 2007 for data from year 2005 and included the research investments made by 19 funders. There are now over 45 organizations tracked and 17 years of research funding data available. The CCRA has published two strategic plans: one for the period 2010-2014 and the other for 2015-2020. In addition, strategic frameworks have been published for prevention (2012), survivorship (2017), and palliative and end-of-life care (2017) research. The CCRA has convened seven major research conferences 2011 (Toronto), 2013 (Toronto), 2015 (Montr al), 2017 (Vancouver), 2019 (Ottawa), 2021 (virtual), and 2023 (Halifax). The CCRA has supported clinical trials through its publication, Report on the State of Cancer Clinical Trials in Canada, (2011) which proposed the creation of the Canadian Cancer Clinical Trials Network (3CTN). 3CTN is now completing its tenth year of operation. Canadian Cancer Research Alliance

  5. 5 MEMBERS* Michael Smith Health Research BC Movember Canada National Research Council Canada New Brunswick Cancer Network Nova Scotia Cancer Care Program Ontario Health - Cancer Care Ontario Ontario Institute for Cancer Research Ovarian Cancer Canada Pancreatic Cancer Canada PROCURE Public Health Agency of Canada Research Manitoba Saskatchewan Cancer Agency Saskatchewan Health Research Foundation Terry Fox Research Institute Alberta Cancer Foundation Alberta Innovates Beatrice Hunter Cancer Research Institute BioCanRx Brain Tumour Foundation of Canada Breast Cancer Canada BC Cancer C17 Research Network Canadian Association of Provincial Cancer Agencies Canadian Association of Radiation Oncology Canadian Cancer Society Canadian Institutes of Health Research Canadian Partnership Against Cancer CancerCare Manitoba Cancer Research Society Quebec Breast Cancer Foundation Fonds de recherche du Qu bec Sant Genome Canada Kidney Foundation of Canada Leukemia and Lymphoma Society of Canada *Bladder Cancer Canada and Myeloma Canada recently became members (October 2023). Canadian Cancer Research Alliance

  6. 6 CANADIAN CANCER RESEARCH SURVEY (CCRS) quantifies and qualifies cancer research investment in Canada by governmental and voluntary organizations in the form of an annual report for use by both Alliance members and the public assists in the identification of significant gaps and potential opportunities in cancer research helps inform strategic alignment on cancer research across Canadian cancer research funders and allied partners Canadian Cancer Research Alliance

  7. 7 PROJECT CLASSIFICATION AREAS OF SCIENCE The Common Scientific Outline (CSO), used by the International Cancer Research Partnership (ICRP), is the principal classification framework. It is organized according to six broad areas of scientific interest: Biology, Etiology, Prevention, Early detection, diagnosis & prognosis, Treatment, and Cancer control, survivorship & outcomes Where more than one CSO code is assigned to a given project, the budget is distributed equally among the codes. Two different coders work independently and code all projects, and then meet to discuss coding discrepancies and determine final codes. Canadian Cancer Research Alliance

  8. 8 PROJECT CLASSIFICATION CANCER SITES The International Statistical Classification of Diseases and Related Health Problems, (ICD-10), Version 2019, a global standard overseen by the World Health Organization, is used for site classification. Disease site coding is based on those sites identified by researchers in the project descriptions. Projects may be assigned more than one cancer site, and in those cases, budget allocations sum to 100% of the total. In those cases where a project is applicable to many cancer sites, the project is coded as non-specific/all sites. Canadian Cancer Research Alliance

  9. 9 REPORT SCOPE Includes over 30,000 projects funded in calendar years 2005 to 2021 by 45 organizations/programs from the governmental and voluntary sectors in Canada (31 CCRA members, and 14 non-member organizations/programs). Projects were subjected to some form of peer review. Research investment is prorated and based on actual allocations over the 17 years and not financial commitments. The survey is estimated to cover most of research funding granted through formal, peer-reviewed funding programs and about 60-80% of all sources of research funding for Canadian cancer research. This presentation highlights data for the 2021 year, but also provides comparisons for the three periods five-year periods: 2007 11, 2012 16, and 2017 21. Canadian Cancer Research Alliance

  10. 10 PARTICIPATING ORGANIZATIONS GOVERNMENT Provincial Cancer Agencies CancerCare Manitoba Nova Scotia Cancer Care Program Nova Scotia Health Authority Ontario Health - Cancer Care Ontario Saskatchewan Cancer Agency Provincial Health Research Organizations Alberta Innovates Fonds de recherche du Qu bec - Sant Michael Smith Health Research BC Newfoundland and Labrador Centre for Applied Health Research Ontario Institute for Cancer Research Ontario Ministry of Colleges and Universities Research Manitoba ResearchNB Research Nova Scotia Saskatchewan Health Research Foundation Federal Government Canada Excellence Research Chairs Canada Foundation for Innovation Canada Research Chairs Program Canada Research Coordinating Committee New Frontiers in Research Fund Canadian Institutes of Health Research Canadian Partnership Against Cancer Genome Canada National Research Council Canada Natural Sciences and Engineering Research Council Networks of Centres of Excellence BioCanRx Public Health Agency of Canada Social Sciences and Humanities Research Council CHARITIES/ASSOCIATIONS Alberta Cancer Foundation Beatrice Hunter Cancer Research Institute Brain Tumour Foundation of Canada Breast Cancer Canada C17 Research Network Canadian Association of Radiation Oncology Canadian Cancer Society Cancer Research Society Cole Foundation Kidney Foundation of Canada Leukemia & Lymphoma Society of Canada Movember Canada Ovarian Cancer Canada Pancreatic Cancer Canada Pediatric Oncology Group of Ontario PROCURE Quebec Breast Cancer Foundation Terry Fox Research Institute Canadian Cancer Research Alliance

  11. 11 REPORTING CONVENTIONS Investments were based on actual funding (e.g., if a grant was administered by one organization but funded by two organizations, each organization s contribution was reflected). The budgets of projects were weighted on the basis of their cancer relevance. For projects that were not entirely focused on cancer, budgets were weighted between 5% and 80%. Analyses by geographic region were based solely on the institutional affiliation of the nominated principal investigator (PI). Canadian Cancer Research Alliance

  12. 12 A1. OVERALL INVESTMENT HIGHLIGHTS FOR 2021 There was $519M invested in 2021 by the 45 organizations/programs tracked in the survey, not marginally different since 2018. The number of funded projects was also fairly similar between the years of 2018 to 2021. Programs/agencies of the federal government accounted for 53% of the investment in 2021. The largest investment was made by the Canadian Institutes of Health Research (CIHR) at $178M, which represented 34% of the total investment in 2021 and 64% of the total federal investment. The overall provincial investment, which includes the matching provincial investments in programs of the Canada Foundation of Innovation, ranged from $110M to $117M annually for years 2017 to 2021 and there were fluctuations (up and down) among individual organizations. Canadian Cancer Research Alliance

  13. 13 A2. OVERALL INVESTMENT HIGHLIGHTS FOR 2021 Among the charitable organizations/associations, the highest level of funding in 2021 was for the Canadian Cancer Society. The other leading research charity was The Terry Fox Research Institute (TFRI). When analyzing across the three time periods, charitable research funders posting successively increased research investments were: Leukemia & Lymphoma Society of Canada, Cancer Research Society, Ovarian Cancer Canada, Pancreatic Cancer Canada, Brain Tumour Foundation of Canada, and Beatrice Hunter Cancer Research Institute. The research investment on a per capita basis was highest for Ontario and Quebec, followed by British Columbia and Alberta. There were differences in the pattern of per capita investment over the three periods for the provinces. Canadian Cancer Research Alliance

  14. 14 CANCER RESEARCH INVESTMENT, 2005 2021 ($M) 582 600 6,000 570 565 561 527 521 520 519 512 489 489 487 487 482 500 5,000 441 390 374 400 4,000 Number $M 300 3,000 200 2,000 100 1,000 0 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Project equivalents [1] Annual investment ($M) [1] Number of projects funded at some point in the calendar year and weighted by cancer relevance. Canadian Cancer Research Alliance

  15. 15 INVESTMENT BY FUNDING SECTOR, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 2007 11 ($2.6B) 45 25 22 8 2012 16 ($2.5B) 44 23 26 6 2017 21 ($2.6B) 51 22 19 8 Federal government organizations/programs [1] Provincial government agencies/organizations Charitable organizations/associations Other partnered/leveraged funding [1] This figure does not include estimates of the federal Research Support Fund (see slide 38). Canadian Cancer Research Alliance

  16. 16 2021 FEDERAL GOVERNMENT INVESTMENT ($276M) [1] Canada Excellence Research Chairs, $1.8M Canada Foundation for Innovation, $27.4M Canada Research Chairs Program, $21.7M Canada Research Coordinating Committee - New Frontiers in Research Fund, $3.3M Canadian Institutes of Health Research, $177.8M Canadian Partnership Against Cancer, $4.8M Genome Canada, $9.8M National Research Council Canada, $3.9M Natural Sciences and Engineering Research Council, $16.5M Networks of Centres of Excellence, $0.6M Networks-BioCanRx, $3.5M Public Health Agency of Canada, $1.2M Social Sciences and Humanities Research Council, $2.0M Other federal agency, $2.0M [1] This figure does not include estimates of the federal Research Support Fund (see slide 38). Canadian Cancer Research Alliance

  17. 2021 VOLUNTARY SECTOR INVESTMENT ($97M) 17 Funding Organization Alberta Cancer Foundation Beatrice Hunter Cancer Research Institute Brain Tumour Foundation of Canada Breast Cancer Canada C17 Research Network Canadian Association of Radiation Oncology Canadian Cancer Society Cancer Research Society Cole Foundation Kidney Foundation of Canada Leukemia & Lymphoma Society of Canada Movember Canada [1] Ovarian Cancer Canada PROCURE Pancreatic Cancer Canada Pediatric Oncology Group of Ontario Quebec Breast Cancer Foundation Terry Fox Research Institute Other charitable organization [2] $ million % 7.61 0.42 0.50 0.32 0.20 0.10 32.63 8.40 1.42 0.15 1.37 2.07 2.55 0.08 0.84 0.01 2.24 15.62 4.64 97.25 9.37 0.51 0.61 0.39 0.24 0.12 40.21 10.35 1.75 0.18 1.69 2.55 3.15 0.09 1.04 0.02 2.76 19.25 5.71 100.00 TOTAL [1] This data for Movember Canada reflects its contribution to research administered by Prostate Cancer Canada, which was amalgamated with the Canadian Cancer Society in 2020. [2] Other charities are groups that are not tracked in the CCRS, but that contribute monies to the research funding programs of organizations tracked in the CCRS. Canadian Cancer Research Alliance

  18. 18 PER CAPITA CANCER RESEARCH INVESTMENT BY PROVINCE OF NOMINATED PRINCIPAL INVESTIGATOR, THREE PERIODS ($) [1,2] $25 2007-2011 2012-2016 2017-2021 $20 $15 $10 $5 $0 B.C. Alta. Sask. Man. Ont. Que. N.B. N.S. P.E.I. N.L. CANADA [1] Excludes trainee awardees studying outside Canada. [2] Provincial population figures from Statistics Canada, Table 17-10-0005-01 - Population estimates on July 1st, by age and sex (accessed 2023-08-17). Canadian Cancer Research Alliance

  19. 19 B1. AREAS OF SCIENCE/CSO - HIGHLIGHTS The 2021 investment by the six categories of the CSO was as follows: $112.1 M Biology $ 60.6 M Etiology $ 11.8 M Prevention $103.9 M Early detection, diagnosis & prognosis $180.8 M Treatment $ 49.8 M Cancer control, survivorship & outcomes The investments in 2017-2021 compared to the periods 2007-2011 and 2012-2016 were lowest for the categories of Biology, Etiology and Prevention but highest for Early detection, diagnosis & prognosis, Treatment, and Cancer control survivorship & outcomes. Plotted over the 17 years, the investment by CSO categories shows the growing investment in early translation as researchers work to identify promising treatments and ways to detect, diagnosis and optimize treatment outcomes. Canadian Cancer Research Alliance

  20. 20 CANCER RESEARCH INVESTMENT BY CSO CATEGORY [1], THREE PERIODS (%) 50.0 40.0 30.0 20.0 10.0 0.0 10.0 20.0 30.0 40.0 50.0 Biology Etiology Prevention Early detection, diagnosis and prognosis Treatment Cancer control, survivorship and outcomes 2007-2011 35 14 3 13 26 9 Proportion of investment (%) 2012-2016 28 13 4 17 29 9 2017-2021 23 12 3 19 35 9 [1] For further information about the Common Scientific Outline (CSO), please see https://www.icrpartnership.org/cso. Canadian Cancer Research Alliance

  21. 21 ANNUAL INVESTMENT BY CSO CATEGORY [1] ($M) 200 180 Treatment 160 Biology 140 120 Early detection, diagnosis and prognosis 100 80 Etiology 60 Cancer control, survivorship and outcomes 40 20 Prevention 0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 [1] For further information about the Common Scientific Outline (CSO), please see https://www.icrpartnership.org/cso. Canadian Cancer Research Alliance

  22. 22 C1. CANCER SITES - HIGHLIGHTS Over half (57%) of the 2021 research investment was relevant to one or more cancer sites. The research investment related to brain cancer, leukemias, and ovarian and pancreatic cancer increased in excess of $25M from the 2007-2011 period to the 2017-2021 period. The breast cancer research investment dropped $34M from 2012-2016 to 2017- 2021. There remains a poor correlation between new cancer cases and cancer deaths (components of disease burden) and site-specific research investment for some cancer sites, with notably discrepancies for lung, colorectal and bladder cancers. New cancer cases and cancer deaths are, however, only part of the broader burden of disease and thus not a comprehensive metric to assess the relative research investment. Canadian Cancer Research Alliance

  23. 23 CANCER RESEARCH INVESTMENT BY CANCER SITE, THREE PERIODS ($M) [1] 0 50 100 150 200 250 300 350 400 Bladder 2007-2011 2012-2016 2017-2021 Bone and connective tissue Brain Breast Cervix Colorectal Esophagus Head and neck (oral and larynx) Hodgkin lymphoma Kidney Leukemias Liver Lung Multiple myeloma Non-Hodgkin lymphoma Ovary Pancreas Prostate Skin (Melanoma) Stomach Thyroid Uterus Other sites [1] For detailed annual investments by cancer site, please consult the supplementary data file available on the CCRA website. Canadian Cancer Research Alliance

  24. 24 SITE-SPECIFIC CANCER RESEARCH INVESTMENT IN 2021 BY NEW CANCER CASES AND CANCER DEATHS IN 2021 (%) 30 % new cases 2021 % deaths 2021 % site-specific investment, 2021 25 20 15 10 5 0 Bladder Brain Breast Colorectal Kidney Leukemias Liver Lung NHL Ovary Pancreas Prostate Data source: Canadian Cancer Registry database at Statistics Canada Canadian Cancer Research Alliance

  25. 25 D1. FUNDING MECHANISMS - HIGHLIGHTS The federal government sector investment, being the largest, also represented the largest portions of investment in operating grants, careers awards, trainee awards, and related support. Research-related support remained a small component of the overall funding mechanism mix, accounting for $0.6M in 2021. National (no regional restrictions) investigator-initiated operating grants represented 42% of 2017 2021 investment ($681M) an increase of $116M over the previous five-year period. Nominated principal investigators working in Ontario, Canada s largest province, received 47% of the total operating grant investment in 2021. Canadian Cancer Research Alliance

  26. 26 D2. FUNDING MECHANISMS - HIGHLIGHTS In 2021, $21.4M was invested trainee awards, which included all levels undergraduate to post- doctorate. The trainee investment in Biology research showed the same declining trend as operating grants for the three time periods highlighted in this report. For all three periods, proportionately more of the investment in trainee awards focused on Cancer control, survivorship and outcomes research. The investment in career awards was cumulatively at the lowest level ($215M) in the 2017-2021 period, although there was increased investment through the Canada Research Chairs program. The cumulative investment in equipment/infrastructure awards rose by $34M in the 2017-2021 period compared to the 2012-2016 period. Institutional support, which for the purposes of the report was an estimate of the cancer component of the federal government s Research Support Fund (RSF), was estimated to be $34.8M in 2021. The RFS assists Canadian postsecondary institutions with the costs associated with managing their research activities. Canadian Cancer Research Alliance

  27. 27 CANCER RESEARCH INVESTMENT BY FUNDING MECHANISM AND SECTOR, 2021 ($M) 300 250 200 150 100 50 0 Federal government agencies/programs Provincial government organizations/programs Charitable Other partnered/leveraged funding organizations/associations Operating grants Equipment/infrastructure grants Career awards Trainee awards Related support grants Canadian Cancer Research Alliance

  28. 28 OPERATING GRANT INVESTMENT BY PROGRAM TYPE, 2021 (%) 1 - Non-site specific; open to all areas of research, $153M, 48% 4 - Site-specific; focused on 1 or more specific research areas, $22M, 7% 3 - Site-specific; open to all areas of research, $2M, 1% 2 - Non-site specific; focused on 1 or more specific research areas, $142M, 44% Canadian Cancer Research Alliance

  29. 29 OPERATING GRANT INVESTMENT BY PROGRAM REACH AND TYPE, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 2007 2011 ($1.4B) 38 37 11 14 2012 2016 ($1.6B) 36 36 7 21 2017 2021 ($1.6B) 42 41 4 13 National investigator initiated National priority driven Regional investigator initiated Regional priority driven Canadian Cancer Research Alliance

  30. 30 OPERATING GRANT INVESTMENT BY PROVINCE OF NOMINATED PRINCIPAL INVESTIGATOR, 2021 (%) N.L. $1.2M, N.S. $4.6M, 1% Sask. $2.8M, 1% Man. $5.3M, 2% B.C. $45.5M, 14% Alta. $27.7M, 9% N.B. $1.0M, less than 1% Que. $80.6M, 25% Ont. $49.8M, 47% Canadian Cancer Research Alliance

  31. 31 CANCER RESEARCH INVESTMENT IN TRAINEE AWARDS AND LEVEL, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 2007 2011 ($129M) 1 36 29 0 17 17 2012 2016 ($136M) 1 32 28 1 17 20 2017 2021 ($117M) 1 40 24 0 18 17 National Undergraduate National Graduate National Postdoctoral Regional Undergraduate Regional Graduate Regional Postdoctoral Canadian Cancer Research Alliance

  32. 32 CANCER RESEARCH INVESTMENT BY FUNDING MECHANISM AND CSO CATEGORY, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 Operating grants 40 11 3 13 25 9 2007-2011 Trainee awards 48 10 3 8 21 11 Operating grants 30 10 3 19 29 9 2012-2016 Trainee awards 37 10 2 12 26 13 Operating grants 24 11 3 20 32 9 2017-2021 Trainee awards 30 10 3 12 30 16 Biology Etiology Prevention Early detection, diagnosis and prognosis Treatment Cancer control, survivorship and outcomes Canadian Cancer Research Alliance

  33. 33 INVESTMENT IN TRAINEE AWARDS BY PROVINCE OF TRAINEE, 2021 (%) N.L., less than 1% P.E.I., less than 1% Sask. $0.2M, 1% N.S. $0.7M, 3% B.C. $3.4M, 17% Alta. $1.4M, 7% Man. $0.4M, 2% N.B. $0.2M, 1% Que. $6.5M, 32% Ont. $7.2M, 36% Canadian Cancer Research Alliance

  34. 34 CAREER AWARD INVESTMENT BY TYPE, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 2007 2011 ($232M) 47 1 13 6 32 2012 2016 ($242M) 45 2 10 10 33 2017 2021 ($215M) 53 2 5 6 35 National funding program - Canada Research Chair [1] National funding program - Other research chair National funding program - Salary award Regional funding program - Research chair Regional funding program - Salary award Canadian Cancer Research Alliance

  35. 35 CAREER AWARD INVESTMENT BY PROVINCE OF NOMINATED PRINCIPAL INVESTIGATOR, 2021 (%) N.L. $0.4M, 1% N.S. $0.2M, less than 1% B.C. $8.4M, 19% N.B. $0.47M, 2% Sask. $0.1M, less than 1% Alta. $3.5M, 8% Man. $0.7M, 2% Que. $10.7M, 24% Ont. $19.4M, 44% Canadian Cancer Research Alliance

  36. 36 EQUIPMENT/INFRASTRUCTURE GRANTS BY TYPE, THREE PERIODS (%) 0 10 20 30 40 50 60 70 80 90 100 2007 2011 ($903M) 68 6 12 14 2012 2016 ($579M) 61 16 14 8 2017 2021 ($612M) 61 16 20 3 National funding program - Infrastructure, equipment and/or maintenance National funding program - Research platform Regional funding program - Infrastructure, equipment and/or maintenance Regional funding program - Research platform Canadian Cancer Research Alliance

  37. 37 EQUIPMENT/INFRASTRUCTURE GRANT INVESTMENT BY PROVINCE OF NOMINATED PRINCIPAL INVESTIGATOR, 2021 (%) Alta. $2.6M, 2% N.L., $0.1, less than 1 % Sask. $2.3M, 2% Man. $5.6M, 4% N.S. $2.1, 2% B.C. $17.5M, 13% Que. $26.4M, 20% Ont. $77.3M, 58% Canadian Cancer Research Alliance

  38. 38 ESTIMATED RESEARCH SUPPORT FUND ($34.8M) BY PROVINCE OF NOMINATED PRINCIPAL INVESTIGATOR, 2021 (%) Sask., $0.4M, 1% N.L., $0.1M, less than 1% Man., $0.5M, 1% Alta., $2.6M, 8% B.C., $4.3M, 12% N.S., $0.4M, 1% Que., $9.6M, 28% Ont., $16.8M, 48% Canadian Cancer Research Alliance

  39. 39 FURTHER INFORMATION This slide deck,supplementary data (Excel), and interactive dashboards (Tableau) are available at http://www.ccra-acrc.ca. Support for this work was made possible through collaboration and financial support from the Canadian Partnership Against Cancer Corporation and Health Canada. We would like to thank the many organizations that participate in the CCRS by contributing their data on an annual basis. Without them, this ongoing work would not be possible. A special thank you to Dr. Jim Hudson, who has provided coding and additional supports to the CCRS since its inception. CCRA is a member of the International Cancer Research Partnership (ICRP), a group of cancer research funding organizations that agree to adhere to common classification standards and share investment data. The survey for the 2022 data year is currently underway. Questions about this project should be directed to the CCRA Program Manager at info@ccra- crc.ca. Canadian Cancer Research Alliance

  40. www.ccra-acrc.ca @CCRAlliance linkedin.com/company/canadian-cancer-research-alliance/ info@ccra-acrc.ca Canadian Cancer Research Alliance

Related


More Related Content